Amberstone Biosciences snags $12m Series A

Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing.

3 January 2022•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

LPs press emerging VCs on quality of their networks

3 November 2026 · 3 mins read

Download the November/December 2026 issue of Venture Capital Journal

2 November 2026 · 1 min read

Bites raises $40m Series A round to expand frontline worker learning platform

29 October 2026 · 7 mins read

OCIO Cerity seeks proof of exits as clients raise bar for venture funds

29 October 2026 · 4 mins read

Matter taps LPs that bring more than money for oversubscribed Fund II

28 October 2026 · 5 mins read

BackingMinds raises €50m for Fund III, focused on Nordic start-ups

26 October 2026 · 3 mins read

Singapore VC plants flag in Ohio in search of US investors

26 October 2026 · 6 mins read